Noémie Wagner

Noémie Wagner

Auto-generated profile, based on publicly available information

Noémie Wagner

Paediatric infectious disease unit, Department of Paediatrics, Gynaecology and Obstetrics, University hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2024 in eClinicalMedicine
Verified
Journal Article
Open access
MKMorgane Kowalski
Morgane Kowalski
BOBasilice Minka Obama
Basilice Minka Obama
GCGaud Catho
Gaud Catho
JDJuan Emmanuel Dewez
Juan Emmanuel Dewez
AMArnaud Merglen
Arnaud Merglen
NWNoémie Wagner
Noémie Wagner
The burden of antimicrobial resistance (AMR) has been estimated to be the highest in sub-Saharan Africa (SSA). The current study estimated the proportion of drug-resistant Enterobacterales causing infections in SSA children. We searched MEDLINE/PubMed, Embase and the Cochrane Library to identify retrospective and prospective studies published from 01/01/2005 to 01/06/2022 reporting AMR of Enterobacterales causing infections in sub-Saharan children (0–18 years old). Studies were excluded if they had unclear documentation of antimicrobial susceptibility testing methods or fewer than ten observations per bacteria. Data extraction and quality appraisal were conducted by two authors independently. The primary outcome was the proportion of Enterobacterales resistant to antibiotics commonly used in paediatrics. Proportions were combined across studies using mixed-effects logistic regression models per bacteria and per antibiotic. Between-study heterogeneity was assessed using the I2 statistic. The protocol was registered with PROSPERO (CRD42021260157). After screening 1111 records, 122 relevant studies were included, providing data on more than 30,000 blood, urine and stool isolates. Escherichia coli and Klebsiella spp. were the predominant species, both presenting high proportions of resistance to third-generation cephalosporins, especially in blood cultures: 40.6% (95% CI: 27.7%–55%; I2: 85.7%, number of isolates (n): 1032) and 84.9% (72.8%–92.2%; I2: 94.1%, n: 2067), respectively. High proportions of resistance to other commonly used antibiotics were also observed. E. coli had high proportions of resistance, especially for ampicillin (92.5%; 95% CI: 76.4%–97.9%; I2: 89.8%, n: 888) and gentamicin (42.7%; 95% CI: 30%–56.5%; I2: 71.9%, n: 968). Gentamicin-resistant Klebsiella spp. were also frequently reported (77.6%; 95% CI: 65.5%–86.3%; I2: 91.6%, n: 1886). High proportions of resistance to antibiotics commonly used for empirical treatment of infectious syndromes were found for Enterobacterales in sub-Saharan children. There is a critical need to better identify local patterns of AMR to inform and update clinical guidelines for better treatment outcomes. No funding was received.

3 October 2024 in Trials
Verified
Journal Article
Open access
PDF file
PSPatrick M. Meyer Sauteur
Patrick M. Meyer Sauteur
MSMichelle Seiler
Michelle Seiler
RTRomy Tilen
Romy Tilen
EOEster Osuna
Ester Osuna
MWMargarete von Wantoch
Margarete von Wantoch
CBChristoph Berger
Christoph Berger
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia (CAP) in school-aged children. Macrolides are the first-line treatment for this infection. However, it is unclear whether macrolides are effective in treating M. pneumoniae CAP, mainly due to limitations in microbiological diagnosis of previous studies. The extensive global use of macrolides has led to increasing antimicrobial resistance. The overall objective of this trial is to produce efficacy data for macrolide treatment in children with M. pneumoniae CAP. The MYTHIC Study is a randomized, double-blind, placebo-controlled, multicenter, non-inferiority trial in 13 Swiss pediatric centers. Previously healthy ambulatory and hospitalized children aged 3–17 years with clinically diagnosed CAP will be screened with a sensitive and commercially available M. pneumoniae-specific IgM lateral flow assay from capillary blood. Mycoplasma pneumoniae infection in screened patients will be verified retrospectively by respiratory PCR (reference test) and IgM antibody-secreting cell enzyme-linked immunospot (ELISpot) assay (confirmatory test for distinguishing between carriage and infection). Patients will be randomized 1:1 to receive a 5-day treatment of macrolides (azithromycin) or placebo. The co-primary endpoints are (1) time to normalization of all vital signs, including body temperature, respiratory rate, heart rate, and saturation of peripheral oxygen (efficacy), and (2) CAP-related change in patient care status (i.e., admission, re-admission, or intensive care unit transfer) within 28 days (safety). Secondary outcomes include adverse events (AEs), as well as antimicrobial and anti-inflammatory effects. For both co-primary endpoints, we aim to show non-inferiority of placebo compared to macrolide treatment. We expect no macrolide effect (hazard ratio of 1, absolute risk difference of 0) and set the corresponding non-inferiority margins to 0.7 and −7.5%. The “at least one” success criterion is used to handle multiplicity with the two co-primary endpoints. With a power of 80% to reject at least one null hypothesis at a one-sided significance level of 1.25%, 376 patients will be required. This trial will produce efficacy data for macrolide treatment in children with M. pneumoniae CAP that might help to reduce the prescription of antibiotics and therefore contribute to the global efforts toward reducing antimicrobial resistance. ClinicalTrials.gov, NCT06325293. Registered on 24 April 2024

1 November 2025 in Swiss Medical Weekly
Verified
Journal Article
Open access
PDF file
RCRudin Christoph
Rudin Christoph
BTBegona Martinez De Tejada
Begona Martinez De Tejada
PPPaolo Paioni
Paolo Paioni
PCPierre Alex Crisinel
Pierre Alex Crisinel
NWNoémie Wagner
Noémie Wagner
CKChristian R. Kahlert
Christian R. Kahlert
With the use of combined antiretroviral therapy (cART), it has become possible to completely and permanently suppress human immunodeficiency virus (HIV) replication. Successful treatment with combined antiretroviral therapy not only makes HIV infection a treatable chronic disease with a near-normal life expectancy, but also reliably prevents horizontal and also vertical virus transmission. In principle, this allows us to dispense with certain preventive measures from the pre-cART era. However, HIV prevention recommendations tend not to be adjusted until it has been proven beyond any doubt that there is no associated risk. This zero-risk strategy still makes HIV infection a special case and contradicts standard medical practice, which almost always also entails some acceptable risk. This hesitant attitude delays adaptations of care and contributes to the stigmatisation of those affected. In addition, it might even violate the ethical principles of beneficence and justice. In this context, there is still an ongoing debate as to whether the credo “U = U” (undetectable = untransmittable) applies to all aspects of vertical transmission. While there is consensus about the safety of vaginal delivery in case of an undetectable maternal viral load, Switzerland is still the only country that has also refrained from providing post-exposure prophylaxis to newborns since 2016 in such cases. Furthermore, when we last revised our Swiss recommendations for the prevention of vertical transmission in 2018, we assumed a balance (equipoise) between the benefits and potential risks of breastfeeding with HIV under optimal conditions. We proposed a shared decision-making process to allow the expectant mother to make her own well-considered decision which is then unconditionally supported by the care team. However, the decision and the associated responsibility is basically left to the woman. Most high-income countries have meanwhile adopted this procedure. Based on a literature review summarised in this article, the question arises as to whether this approach is still justified. We came to the conclusion that the potential risks of breastfeeding with HIV are being overemphasised, as benefits of breastfeeding, including reductions in morbidity and mortality for both mother and child appear to clearly outweigh these apparently very low risks, even in high-income settings. We therefore believe that breastfeeding with HIV should be favoured and encouraged and not just supported under optimal circumstances and that the care teams should take a clear position in this regard. This will facilitate decision-making for affected women, reduce stigma, relieve the parent(s) of taking on primary responsibility for the decision and further “normalise” HIV infection.

31 March 2023 in Paediatrica Stoffwechsel/rare disease
Verified
Journal Article
Closed access
RGRenato Gualtieri
Renato Gualtieri
KPKlara Posfay-Barbe
Klara Posfay-Barbe
NWNoémie Wagner
Noémie Wagner
Die Evidenz deutet darauf hin, dass in Ländern mit hohem Einkommen eine systematische Antibiotikabehandlung der Streptokokkenangina nicht mehr notwendig ist. Sie sollte auf Sonderfälle beschränkt werden. Wir besprechen die Gründe für diese Änderung und schlagen einen Algorithmus zur Betreuung dieser Patienten vor.

31 March 2023 in Paediatrica
Verified
Journal Article
Closed access
RGRenato Gualtieri
Renato Gualtieri
KBKlara Posfay Barbe
Klara Posfay Barbe
NWNoémie Wagner
Noémie Wagner
Les évidences suggèrent que dans les pays à revenu élevé, une antibiothérapie n’est plus systématiquement nécessaire pour traiter l’angine à streptocoque. Elle devrait être limitée à des cas particuliers. Nous présentons l’argumentaire de ce changement d’attitude et proposons un algorithme de prise en charge.